{"id":990157,"date":"2026-08-05T08:25:41","date_gmt":"2026-08-05T12:25:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/"},"modified":"2026-08-05T08:25:41","modified_gmt":"2026-08-05T12:25:41","slug":"altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/","title":{"rendered":"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026"},"content":{"rendered":"
\n

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc.<\/a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.<\/p>\n

Altimmune management will host a conference call at 8:30 a.m. ET on August 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune\u2019s Investor Relations website<\/a>.<\/p>\n

Participants who would like to join the call may register here<\/a> to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.<\/p>\n

\n About Altimmune<\/strong>\n <\/p>\n

Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company\u2019s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit\u00a0www.altimmune.com<\/u><\/a>.<\/p>\n

\n Follow @Altimmune, Inc. on <\/strong>
\n
\n LinkedIn<\/strong>
\n <\/a>
\n
\n Follow @AltimmuneInc on <\/strong>
\n
\n X<\/strong>
\n <\/a>\n <\/p>\n

\n Investor Contact:<\/strong>
\n
Luis Sanay, CFA
Vice President, Investor Relations
ir@altimmune.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Real Chemistry
altimmune@realchemistry.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on August 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune\u2019s Investor Relations website. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months. About Altimmune Altimmune is a … <\/p>\n

Continue reading “Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-990157","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAltimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on August 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune\u2019s Investor Relations website. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months. About Altimmune Altimmune is a … Continue reading "Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-05T12:25:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDAwMyM3NzU5NDQzIzIwMTA2NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026\",\"datePublished\":\"2026-08-05T12:25:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/\"},\"wordCount\":216,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDAwMyM3NzU5NDQzIzIwMTA2NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/\",\"name\":\"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDAwMyM3NzU5NDQzIzIwMTA2NzY=\",\"datePublished\":\"2026-08-05T12:25:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDAwMyM3NzU5NDQzIzIwMTA2NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgwNDAwMyM3NzU5NDQzIzIwMTA2NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/","og_locale":"en_US","og_type":"article","og_title":"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - Market Newsdesk","og_description":"GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on August 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune\u2019s Investor Relations website. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months. About Altimmune Altimmune is a … Continue reading \"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-05T12:25:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDAwMyM3NzU5NDQzIzIwMTA2NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026","datePublished":"2026-08-05T12:25:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/"},"wordCount":216,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDAwMyM3NzU5NDQzIzIwMTA2NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/","name":"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDAwMyM3NzU5NDQzIzIwMTA2NzY=","datePublished":"2026-08-05T12:25:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDAwMyM3NzU5NDQzIzIwMTA2NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgwNDAwMyM3NzU5NDQzIzIwMTA2NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-to-report-second-quarter-2026-financial-results-and-provide-business-update-on-august-12-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/990157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=990157"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/990157\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=990157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=990157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=990157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}